

## **Consensus of Analysts' Estimates**

The consensus is the median of analyst estimates which are compiled and calculated by Vara Research. It is based on the projections made by analysts covering Solvay. Any opinions, estimates or forecasts regarding Solvay's performance made by these analysts and therefore also the consensus figures are theirs alone and do not represent opinions or forecasts of Solvay or its Management. By making this consensus information of its results available on a quarterly basis, Solvay does not mean or otherwise imply to endorse such information.

Target price (median)	€ 113.5	BUY	43%
Nb. participants	14	HOLD	50%
Consensus date	08/07/2019	SELL	7%



		PRO FORMA 2018 <sup>(7)</sup>							ESTIMATES inclduing the impact of IFRS16					
									Automatic	Pls. fill in	Pls. fill in	Pls. fill in		
	€ million	Q1 2018	Q2 2018	Q3 2018	Q4 2018	FY 2018	Q1 2019	Q2 2019	H2 2019	FY 2019	FY 2020	FY 2021		
	Net sales	2,492	2,600	2,591	2,574	10,257	2,571	2,622	5,280	10,474	10,780	11,159		
	Advanced Materials, sales	1,087	1,123	1,082	1,093	4,385	1,124	1,131	2,231	4,475	4,653	4,848		
	Advanced Formulations, sales	730	775	788	764	3,057	728	753	1,569	3,053	3,123	3,241		
	Performance Chemicals, sales	671	701	720	716	2,808	718	733	1,475	2,929	3,003	3,070		
	Corporate and Business Services, sales	4	1	1	1	7	2	2	3	7	7	8		
	(a)	558	643	599	531	2,330	571	594	1,139	2,315	2,417	2,540		
	Advanced Materials, EBITDA	295	349	299	282	1,225	290	307	582	1,170	1,238	1,302		
Underlying (2)	Advanced Formulations, EBITDA	121	147	143	122	533	126	137	263	526	548	584		
erlyi	Performance Chemicals, EBITDA	185	195	200	180	761	206	209	401	817	826	838		
Dud	Corporate and Business Services, EBITDA	-44	-49	-44	-53	-189	-51	-50	-101	-203	-200	-205		
	Depreciation & amortization (excluding PPA <sup>(3)</sup> )	-186	-193	-192	-206	-777	-195	-198	-396	-784	-802	-793		
	EBIT (excluding non-recurring elements & M&A effects) Net Imancial charges (including coupons of perpetuer hybrid	372	450	407	325	1,554	376	396	742	1,512	1,630	1,723		
	handa(4) \	-89	-81	-88	-82	-341	-89	-82	-161	-327	-296	-283		
	Income taxes	-67	-87	-76	-73	-303	-72	-81	-154	-306	-327	-354		
	Profit from discontinuing operations	41	65	63	47	216	82	40	0	120	0	0		
	Profit attributable to non-controllng interests	-10	-10	-11	-10	-40	-9	-10	-21	-40	-40	-42		
	Profit attributable to Solvay shareholder	246	337	295	208	1,085	289	263	414	985	947	1,050		
IFRS	EBIT, IFRS	146	300	311	236	994	278	336	550	1,135	1,298	1,439		
正	Profit attributable to Solvay shareholder, IFRS	107	223	275	246	852	-	224	324	781	774	903		
Other Indicators	Gross DPS (€) <sup>(6)</sup>					3.75	-	-	-	3.85	4.00	4.10		
	Capex (continuing operations)	-180	-184	-187	-243	-794	-179	-195	-447	-799	-805	-821		
	Free cash flow to Solvay shareholder (total) (5)	141	-65	195	454	725	-32			549	584	708		
	Free cash flow to Solvay shareholder (continuing operations)	100	-118	146	438	566	-91			483	568	666		
	Underlying net debt (including perpetual hybrid bonds)					5,538	5,797	5,968		4,314	4,077	3,763		

Items not contributed by more than 5 analysts will not be displayed as not sufficiently representative

(1) ADVANCED MATERIALS: Specialty Polymers, Composite Materials, Silica, Special Chem; ADVANCED FORMULATIONS: Novecare, Technology Solutions, Aroma Performance; PERFORMANCE CHEMICALS: Soda Ash, Peroxide, Functional Polymers (in dscops since Sep'17), Coatis.

(2) For full disclosure and definition of Underlying alternative metrics on a proforma basis, please refer to appropriate press releases issued by Solvay on Feb 25 and March 17, 2016.

- (3) Purchase Price Allocation.
- (4) Global annual coupon of ~(112)m up to 2018
- (5) Cash flow from operating activities (including dividends from associates and joint ventures) + cash flow from investing activities (excluding acquisitions and sales of subsidiaries and other investments) and excluding loans to associates and non-consolidated companies).
- (6) 2018 Dividend Per Share pending for approval at the General Shareholder meeting

(7) Unaudited 2018 prp forma financial information concerning the adoption of IFRS 16 "Leases". The Group adopted IFRS 16, using a modified retrospective approach, as of January 1, 2019, i.e. without restating prior reporting periods presented. The pro forma information presents the impact on the Group's financial reporting as if the adoption of IFRS 16 had taken place on January 1, 2018. This pro forma financial information only pertains to leases that were classified as operating leases in accordance with IAS 17.